Pharmaceutical giant Eli Lilly has filed lawsuits against six U.S. companies for allegedly selling black-market versions of its experimental weight-loss drug, Retatrutide. Here is the key context: · Drug is still experimental: Retatrutide is currently in Phase 3 clinical trials and has not been approved by the FDA for any use. Selling it commercially is illegal. · Where it was sold: The lawsuits target a network of compounding pharmacies, medical spas, and online resellers. · The danger: Eli Lilly’s Chief Medical Officer stated, “What is being sold on the black market is not a medicine — it is entirely unverified, unapproved and not worth the risk”. What this means for us: This case is a powerful reminder about the importance of drug safety and regulatory compliance. It highlights the dangers of the unregulated online pharmaceutical market and the responsibility of companies to protect public health. Let’s stay informed and prioritize verified, safe medical practices.

We all know Semaglutide and Tirzepatide. But 2026 is the year of Retatrutide—and it completely rewrites the metabolic playbook. Here’s the breakdown your endocrinology rotation won't teach you (yet): 🔬 The Mechanism (3-for-1) Retatrutide is the first triple agonist: → GLP-1 (appetite suppression) → GIP (enhances insulin sensitivity, reduces nausea) → Glucagon (THIS is the game-changer) ⚡ Why Glucagon matters: For decades, we suppressed glucagon. Now we're activating it—in a pulsatile way. It directly stimulates energy expenditure (calorie burn) rather than just calorie restriction. In Phase 2 trials, subjects lost ~24% body weight at 48 weeks—a full 10% more than Tirzepatide—without a massive increase in side effects. 🧠 The "Oh Wow" for Med Students: Retatrutide showed unprecedented reduction in liver fat fraction (over 70% decrease in 24 weeks). That means it's currently being fast-tracked for MASH (Metabolic Dysfunction-Associated Steatohepatitis)—a condition with exactly zero good oral options right now. 📉 The Clinical Catch: Heart rate increases by ~5-10 bpm in the first 8 weeks. It's dose-dependent, it plateaus, and it's reversible—but if your patient has uncontrolled hypertension or pre-existing CAD, you pause and think twice. This isn't a "give and forget" drug. The Bigger Picture Takeaway: We are watching metabolic medicine shift from "restrict calories" to "restructure energy homeostasis." The receptor combinatorics alone (GLP-1 + GIP + Glucagon, or GLP-1 + Amylin + Calcitonin in future candidates) is becoming its own subspecialty. --- 🔬 Journal Club Question for the comments: If you had a 45-year-old obese patient with HFpEF (heart failure with preserved ejection fraction) and MASH—and their insurance denies Retatrutide—what's your second-line peptide alternative, and why? (Drop your reasoning—let's crowdsource this clinical dilemma.) 👇

We all learned that small molecules (<500 Da) hit enzymes, and biologics (mAbs) hit extracellular targets. But what about the "undruggable" protein-protein interactions inside cells? (Looking at you, MYC and RAS). Enter the game-changer: Stapled Alpha-Helical Peptides. 🔬 What they are: Synthetic peptides reinforced with a hydrocarbon "staple" that locks them into a 3D helical shape. This lets them: → Slip straight through the cell membrane (oral/IV potential). → Bind to flat protein surfaces with massive surface area (something small molecules can't do). → Target transcription factors like p53 and MYC—the "Death Star" of oncology. 📈 Why it's hot right now (2025/2026): Phase 2 trials are actively running for stapled peptides targeting KRAS G12D and Wnt/β-catenin pathways. We are watching the first generation of intracellular peptide therapeutics clear clinical hurdles—not as topicals, not as injectable research chems, but as legitimate targeted oncologics. 🧪 The chemist’s flex: The staple is formed via olefin metathesis (yes, the same reaction that won the Nobel in 2005). Ring-closing metathesis locks the side-chains together, decreasing the entropic penalty of binding by ~200-fold. The takeaway for future clinicians/researchers: We aren't just replacing antibodies anymore. We are invading the nucleus. If your pharmacology professor still says "peptides are just poor drugs," show them the latest data on ALRN-6924 (a stapled p53 reactivator). --- Let's discuss: If you could design a staple peptide to inhibit any transcription factor in human disease, which one are you targeting—and why? Drop your hot take below. 👇

Texas just passed a new law that makes 1 gram of THC concentrate a state jail felony—and 4 grams could land you 20 years. Sounds extreme, right? But here’s the thing: we’ve done this before. In the 1980s, we handed out massive mandatory sentences for small amounts of crack cocaine, and we’re still dealing with the fallout. On this episode of Pep in Your Step, we’re breaking down the Texas THC ban, comparing it to the historical crack cocaine crackdown, and asking the bigger question that drives this whole channel—what actually separates a "stimulant" from a "drug"? Coffee? Sugar? THC? Cocaine? Texas puts crack in Penalty Group 1 (their most dangerous category) and THC in Penalty Group 2 (a lower tier)—yet they're giving both nearly identical felony time. If the state admits THC is a lower-tier danger, why are they punishing it like crack? History is repeating itself, and we need to talk about it. Drop a comment: Do you think a gram of wax deserves the same sentence as a crack rock? Let’s debate.

New month. New goals. New results. I'm launching a 30-Day Transformation Challenge for the community — and I want YOU to join. Here's how it works: 1. Set a goal — fat loss, muscle gain, better sleep, more energy. Pick one. 2. Choose your protocol — based on what you've learned in our courses. 3. Track everything — use the tracker template I shared. 4. Check in daily — post your progress in the challenge thread. 5. Finish strong — at the end of 30 days, share your results. Prizes: · 🥇 Free 1-on-1 consultation with me · 🥈 Custom protocol design · 🥉 Shoutout in the community How to join: Drop a comment below with: · Your goal · Your starting point · Your protocol (if you have one) Let's do this together. 👟